PFE vs SLB: Which Is the Better Buy?
Side-by-side comparison of Pfizer Inc. and Slb N.V. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
VS
Slb N.V. · Energy
$52.08
+8.6% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+12.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PFE |
SLB |
| Current Price |
$27.64 |
$52.08 |
| Fair Value Estimate |
$30.94 |
$56.56 |
| Upside to Fair Value |
+12.0%
|
+8.6%
|
| Market Cap |
$157.5B |
$77.3B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
17.4x
|
12.2x
|
| Price / Sales |
2.5x
|
2.1x
|
| Price / FCF |
14.3x
|
17.1x
|
| Revenue Growth YoY |
+2.6%
|
+5.0%
|
| Gross Margin |
71.3%
|
16.5%
|
| Operating Margin |
25.1%
|
13.4%
|
| Return on Equity |
4.9%
|
11.8%
|
| Dividend Yield |
6.22% |
2.25% |
| FCF Yield |
6.97%
|
5.83%
|
| Analyst Consensus |
Hold
|
Strong Buy
|
Investment Thesis
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
SLB N.V. is the world's largest oilfield services provider, operating four divisions (Digital & Integration, Reservoir Performance, Well Construction, and Production Systems) that span field development, drilling, subsea production, and carbon management for the global energy industry. The business carries a medium-quality profile: it benefits from deep technical expertise, a broad international …
Accumulation Zones
| Metric |
PFE |
SLB |
| Zone Low |
$23.21 |
$42.42 |
| Zone High |
$26.30 |
$48.08 |
| In Buy Zone? |
No
|
No
|